ADT Inc. (ADT)
NYSE: ADT · Real-Time Price · USD
7.55
0.00 (0.00%)
Nov 20, 2024, 4:00 PM EST - Market closed
ADT Inc. Employees
ADT Inc. had 14,300 employees as of December 31, 2023. The number of employees decreased by 7,700 or -35.00% compared to the previous year.
Employees
14,300
Change (1Y)
-7,700
Growth (1Y)
-35.00%
Revenue / Employee
$359,462
Profits / Employee
$62,026
Market Cap
6.78B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 14,300 | -7,700 | -35.00% |
Dec 31, 2022 | 22,000 | -3,000 | -12.00% |
Dec 31, 2021 | 25,000 | 4,500 | 21.95% |
Dec 31, 2020 | 20,500 | 3,000 | 17.14% |
Dec 31, 2019 | 17,500 | -1,500 | -7.89% |
Dec 31, 2018 | 19,000 | 1,000 | 5.56% |
Dec 31, 2017 | 18,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Ryder System | 47,500 |
Alaska Air Group | 26,043 |
Valmont Industries | 11,125 |
Beacon Roofing Supply | 8,063 |
MSA Safety | 5,100 |
Casella Waste Systems | 4,200 |
Armstrong World Industries | 3,100 |
CSW Industrials | 2,600 |
ADT News
- 23 days ago - ADT Announces Pricing of Secondary Public Offering of Common Stock and Concurrent Share Repurchase - GlobeNewsWire
- 24 days ago - ADT Announces Launch of Secondary Public Offering of Common Stock and Concurrent Share Repurchase - GlobeNewsWire
- 27 days ago - ADT Inc. (ADT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - ADT Reports Third Quarter 2024 Results - GlobeNewsWire
- 4 weeks ago - ADT To Release Third Quarter 2024 Results On Thursday, Oct. 24, 2024 - GlobeNewsWire
- 6 weeks ago - Home security firm ADT Inc reports unauthorized activity on its network - Reuters
- 2 months ago - ADT Inc.: Leading Player In US Home Security Solutions - Seeking Alpha
- 2 months ago - Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer - GlobeNewsWire